問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鍾啟禮

Recruiting

List

62Cases

2023-10-16 - 2027-06-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2024-01-01 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

2023-04-01 - 2026-11-30

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-06-01 - 2030-06-30

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-03-10 - 2027-03-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-04-01 - 2029-08-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2023-08-01 - 2027-04-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-04-01 - 2027-08-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2018-09-01 - 2022-03-31

Phase III

PONENTE: A multicenter, open-label, Phase 3b trial for adult patients with severe eosinophilic leukocyte asthma who are treated with high-dose corticosteroid inhalers, plus long-acting beta 2 agonists and oral corticosteroids for long-term treatment, to evaluate subcutaneously Efficacy and safety of 30 mg injection of Benralizumab for reducing oral corticosteroid dosage

  • Condition/Disease

    Severe eosinophilic leukocyte asthma

  • Test Drug

    Benralizumab

Participate Sites
8Sites

Recruiting8Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

郭漢彬
Taipei Medical University Hospital

Division of Thoracic Medicine

2018-09-01 - 2020-02-29

Phase I

A Phase I, open-label study to evaluate safety and tolerability of PB101 in combination with standard treatment, EGFR-TKI (Gefitinib or Erlotinib), in EGFR-mutated advanced non-small cell lung cancer.

  • Condition/Disease

    EGFR-mutated advanced non-small cell lung cancer

  • Test Drug

    PB101

Participate Sites
2Sites

Recruiting2Sites

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB